If you are based in Estonia, Finland, Hungary, Iceland, Ireland, Liechtenstein, Luxembourg, Poland, Slovenia or Sweden, and you would like to learn more, or have a discussion about Fintepla (fenfluramine) and its indication for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older,1 our Key Account Manager (KAM) Olivia will be able to help.
Alternatively, if you have a Medical Information query please contact Medical Information on +44 (0) 800 060 8767 or email firstname.lastname@example.org
Digital Key Account Manager Europe
+44 (0) 1530 686 148
+44 (0) 759 989 21 81
Hello, my name is Olivia and I am your Zogenix Account Manager.
My origin is Polish, but I was born and grew up in Berlin, Germany.
I am proud to work for Zogenix International Limited in your country, as a Digital Key Account Manager introducing Fintepla.
Why am I doing this role? The answer is very easy, I get a huge amount of satisfaction from knowing that I could play a part in potentially improving a patient’s life. I speak a number of languages and am very much looking forward to talking with you soon.
If you are a healthcare professional practising in a country not listed above and you have a medical enquiry, then please contact Medical Information on +44 (0) 800 060 8767 or email email@example.com
- Fintepla Summary of Product Characteristics.